CARsgen Therapeutics repurchases shares, increasing treasury holdings

CARsgen Therapeutics Holdings Limited submitted its Next Day Disclosure Return on December 12, 2025, detailing significant share repurchase activity. On December 12, 2025, the company repurchased 250,000 ordinary shares on the Exchange. The repurchase price per share ranged from HK$15.45 to HK$15.65, with an aggregate price paid of HK$3,894,475.

These repurchased shares are being held as treasury shares, increasing the total number of treasury shares to 5,174,000, up from 4,924,000 on December 11, 2025. This repurchase represents 0.04% of the existing number of issued shares (excluding treasury shares) prior to the event.

As a result of this transaction, the number of issued shares (excluding treasury shares) decreased by 250,000 to 572,799,155 as of December 12, 2025. The total number of issued shares, including treasury shares, remains at 577,973,155.

The company also disclosed that it is authorized to repurchase a total of 57,543,590 shares under a mandate granted on May 22, 2025. Cumulatively, 5,629,000 shares have been repurchased on the Exchange under this mandate, representing 0.978% of the issued shares (excluding treasury shares) as of the mandate date. A moratorium period for new share issues or treasury share transfers is in effect until January 11, 2026.